Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2006-10-10
2006-10-10
Parkin, Jeffrey S. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S141100, C424S142100, C530S387100, C530S388100, C530S388150, C530S388750
Reexamination Certificate
active
07118859
ABSTRACT:
This invention provides an antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein+cell with an appropriate CD4+cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and capable of inhibiting infection by one or more strains of HIV-1. This antibody is then used to identify a molecule which is important for HIV infection. Different uses of the antibody and the molecule are described.
REFERENCES:
patent: 5071964 (1991-12-01), Dustin et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5854400 (1998-12-01), Chang et al.
patent: 5994515 (1999-11-01), Hoxie
patent: 6107019 (2000-08-01), Allaway et al.
patent: 6261763 (2001-07-01), Allaway et al.
patent: 6344545 (2002-02-01), Allaway et al.
patent: 6759519 (2004-07-01), Li et al.
patent: 2002/0045161 (2002-04-01), Allaway et al.
patent: 2002/0155429 (2002-10-01), Allaway et al.
patent: 2003/0228306 (2003-12-01), Olson et al.
patent: 2004/0228869 (2004-11-01), Olson et al.
patent: WO 95/16789 (1994-12-01), None
patent: WO 96/41020 (1996-12-01), None
patent: WO 97/37005 (1997-10-01), None
patent: WO 97/45543 (1997-12-01), None
patent: WO 97/47319 (1997-12-01), None
patent: WO 97/49424 (1997-12-01), None
patent: WO 98/56421 (1998-12-01), None
patent: WO 00/35409 (2000-06-01), None
Max, E., “Immunoglobulins: Molecular Genetics”, in Fundamental Immunology, Fourth Edition, W. E. Paul, ed., Lippincott-Raven Publishers, Philadelphia, 1999, pp. 142-143.
Madden PJ., Dalgleish AG., McDougal JS., Clapham PR., Weiss RA., and Axel R., (1986) “The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain” Cell 47:333-348.
Queen et al., (1989) “A Humanized Antibody That Binds to The Interleukin 2 Receptor”Proc. Natl. Acad. Sci.86:10029-10033.
Sato et al., (1992) “Anti-CD7 Reagents Inhibit HIV-1 Induced Syncytium Formation”International Conf.AIDS81:PA5, POA2017.
Sato AI., Balamuth FB., Ugen KE., Williams WV., and Weiner DB., (1994) “Identification of CD7 glycoprotein as an accessory molecule in HIV-1-mediated syncytium formation and cell free infection” J. Immunol. 152:5142-5152.
Sato, A.I., et al., (1995), “A simple and rapid method for preliminary evaluation of in vivo efficacy of anti-HIV compounds in mice”Antivir. Res.27: 151-163.
Schanberg et al., (1995), “Characterization of Human CD7 Transgenic Mice”J. of Immun.146:507-514.
Sommerfelt, M.A., et al., (1995), “Intercellular adhesion molecule 3, a candidate human immunodeficiency virus type 1 co-receptor on lymphoid and monocytoid cells”J. Cen. Virol.76: 1345-1352.
Tulip, W.R., et al., (1992), “Crystal structures of two mutant neuraminidase-antibody complexes with amino acid substitutions in the interface” J. Mol. Biol. 227: 149-159.
Valentin et al., (1990) “The Leukocyte Adhesion Glycoprotein CD18 Participates In HIV Induced Syncyia Formation In Monocytoid and T-Cells”Eur. J. Immunol. 24:1553-1557.
Wang et al., (1994) “Deletion of T Lymphocytes In Human CD4 Transgenic Mice Induced By HIV-gp120 and gp120-Specific Antibodies From AIDS Patients”Eur. J. Immunol.24:1553-1557.
Abaza, M.-S.I. and M.Z. Atassi, (1992), “Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptid immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin”J. Prot. Chem.11(5): 433-443.
U.S. Appl. No. 09/118,415, filed Jul. 17, 1998, Litwin et al.
Alexander, H., et al., (1992), “Altering the antigenicity of proteins”Proc. Natl. Acad. Sci. USA89: 3352-3356.
Ashorn PA., Berger EA., and Moss B. (1990) “Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells”J. Virol.64:2149-2156.
Attanasio et al. (1991) “Anti-Idiotypic Antibody Response To Monoclonal Anti-CD4 Preparations In Non-Human Primate Species”J. Immun.146:507-514.
Broder CC., Dimotrov DS., Blumenthal R., and Berger EA (1993) “The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s)” Virology 193;483-491.
Busso et al., (1991) “HIV-Induced Syncytium Formation Requires The Formation of Conjugates Between Virus-Infected And Uninfected T-Cells In Vitro”AIDS5:1425-1432.
Clapham PR., Blac D., and Weiss RA., (1991) “Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus” Virology 181:703-715.
Dalgleish AG. (1995) “HIV and CD26” Nature Medicine 1:881-882.
Dragic T., Charneau P., Clavel F., and Alizon M., (1992) “Complementation of murine cells for human immunodeficiency virus envelope/CD4-mediated fusion in human/murine heterokaryon” J. Virol. 66:4794-4802.
Dragic T., Picard L., and Alizon M., (1995) “Proteinase-resistant factors in human erythrocyte membranes mediate CD4-dependent fusion with cells expressing human immunodeficiency virus type 1 envelope glycoproteins” J. Virol. 69:1013-1018.
Golding H., Dimitrov DS., and Blumenthal R., (1992) “LFA-1 adhesion molecules are not involved in the early stages of HIV-1 env-mediated cell membrane fusion” AIDS Res. Hum. Retroviruses 8:1593-1598.
Harrington RD., and Geballe AP., (1993) “Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line” J. Virol. 67:5939-5947.
Hattori et al., (1989) “Involvement of a Tryptase-Related Cellular Protease(s) In Human Immunodeficiency Virus Type I Infection”FEBS Letters248:48-52.
Hildreth et al., (1989) “Involvement of A Leukocyte Adhesion Receptor (LFA-1) In HIV-Induced Syncytium Formation”Science244:1075-1078.
Jacobson, J.M., et al., (1993), “Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection” J. Infect. Dis. 168: 298-305.
Karwowska, S., et al., (1991), “Passive immunization for the treatment and prevention of HIV infection”Biotech. Therap.2(1-2): 31-48.
Katinger, H., (1994), “Human monoclonal antibodies for passive immunotherapy of HIV-1”Antibiot. Chemother.46: 23-27.
G.P. Allaway, U.S. Appl. No. 08/169,311, filed Dec. 17, 1993 (now abandoned).
G.P. Allaway, U.S. Appl. No. 08/475,515, filed Jun. 7, 1995 (now abandoned).
G.P. Allaway et al., U.S. Appl. No. 08/627,684, filed Apr. 2, 1996 (now abandoned).
G.P. Allaway et al., U.S. Appl. No. 60/014,532, filed Apr. 2, 1996.
G.P. Allaway et al., U.S. Appl. No. 08/663,616, filed Jun. 14, 1996 (now abandoned).
G.P. Allaway et al., U.S. Appl. No. 08/673,682, filed Jun. 25, 1996 (now abandoned).
Allowed claims in G.P. Allaway et al., U.S. Appl. No. 09/412,284, filed Oct. 5, 1999.
Pending claims in G.P. Allaway et al., U.S. Appl. No. 09/460,216, filed Dec. 13, 1999.
G.P. Allaway et al., U.S. Appl. No. 08/665,090, filed Jun. 14, 1996, (now abandoned); and.
Pending claims in G.P. Allaway et al., U.S. Appl. No. 09/724,105, filed Nov. 28, 2000.
Allaway Graham P.
Litwin Virginia M.
Maddon Paul J.
Cooper & Dunham LLP
Parkin Jeffrey S.
Progenics Pharmaceuticals Inc.
White, Esq. John P.
LandOfFree
Methods for inhibiting HIV-1 infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting HIV-1 infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting HIV-1 infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3681755